1. Introduction {#sec1-ijms-19-02090}
===============

Nuclear receptors (NRs) are ligand-dependent transcription factors that regulate DNA transcription by binding small molecular agonists such as hormones. Forty-eight structurally conserved kinds of NRs have been identified, and many of them recognize endogenous steroidal ligands ([Figure 1](#ijms-19-02090-f001){ref-type="fig"}). Because NRs control diverse biological functions including reproduction, differentiation, homeostasis, and the immune system, they were the targets of approximately 5% of FDA-approved drugs in 2011 \[[@B1-ijms-19-02090]\]. However, not only a steroidal ligand, but also its metabolites, brings with it the potential to cross-react with other nuclear receptors, which can result in unwanted side effects, potentially limiting the clinical utility of these agents. Therefore, surrogates for the steroid skeleton are required to develop selective non-steroidal NR ligands for clinical use \[[@B2-ijms-19-02090]\].

The number of fold structures of human proteins is at least 50 times smaller than the number of human proteins \[[@B2-ijms-19-02090]\]. This fact indicates that a scaffold that is spatially complementary to one-fold structure might serve as a common scaffold for ligands that would interact specifically with more than 50 different human proteins, neglecting interactions of the peptide sequences of the proteins. In other words, the structures of ligands that bind to one member of fold structures may be useful for the development of novel lead compounds for other proteins with the similar fold structure. However, lead compounds obtained based on this approach are likely to possess polypharmacological character. Therefore, chemical modification of polypharmacological lead compounds, aimed at optimizing selectivity for a particular target, is required. Since the fold structures of NR ligand-binding domains (LBDs) are similar, we have used this strategy to create ligands bearing a diphenylmethane skeleton for several NRs, including farnesoid X receptor \[[@B3-ijms-19-02090]\], liver X receptor (LXR) \[[@B4-ijms-19-02090]\], vitamin D receptor \[[@B5-ijms-19-02090]\], androgen receptor (AR) \[[@B6-ijms-19-02090]\], and estrogen receptor \[[@B7-ijms-19-02090]\].

We have previously developed LXRs antagonist **1** \[[@B8-ijms-19-02090]\], retinoic acid receptor-related orphan receptors (RORs) inverse agonist **2** \[[@B9-ijms-19-02090]\], progesterone receptor (PR) antagonist **3** \[[@B10-ijms-19-02090]\], and pharmacological chaperones **4** and **5** for Niemann-Pick disease type C1 (NPC1) \[[@B11-ijms-19-02090]\] and Niemann-Pick type C1-like 1 (NPC1L1) ([Figure 1](#ijms-19-02090-f001){ref-type="fig"}) \[[@B12-ijms-19-02090]\]. These compounds all contain a phenanthridin-6(5*H*)-one skeleton as a cyclized carba-analog of the skeleton of LXRs pan agonist T0901317 (**6**). Because endogenous ligands for the above proteins (LXRs, RORs, PR, NPLC1 and NPC1L1) all have a steroid skeleton, we hypothesized that if the phenanthridin-6(5*H*)-one scaffold acts as a steroid surrogate, phenanthridinone derivatives would also bind to other NRs that recognize endogenous steroidal ligands. The approach described here is expected to be useful in the development of novel steroid surrogates, such as the phenanthridinone skeleton, enabling efficient lead finding of ligands for target proteins that recognize endogenous steroidal ligands, and the generation of more selective ligands by further molecular modifications of new and convenient scaffolds (easy to synthesis, easy to introduce substitutent(s) at any position, etc.), compared to the steroid skeleton. Here, we show that application of this approach to our small library of phenanthridinone-based RORs inverse agonists and PR antagonists led to several selective LXRβ, AR and glucocorticoid receptor (GR) antagonists.

2. Results and Discussion {#sec2-ijms-19-02090}
=========================

AR and GR, members of NRs, recognize endogenous steroidal ligands as shown in [Figure 1](#ijms-19-02090-f001){ref-type="fig"}. In addition, because LXRs antagonistic activities of only limited numbers of phenanthridinone analog have been reported \[[@B8-ijms-19-02090]\], precise structure-activity relationships (SAR) remain unclear. Therefore, we exhaustively evaluated our small library of RORs inverse agonists and/or PR antagonists bearing a phenanthridinone skeleton for LXRα, LXRβ, AR and GR antagonistic activities, and examined their SAR. LXRs regulate ATP-binding cassette proteins (ABCs), ApoE and glucose transporter 4 (GLUT4), are involved in lipid metabolism, reverse cholesterol transport, and glucose transport, so LXRs agonists are likely to be of therapeutic value in the treatment of atherosclerosis, hyperlipidemia, and metabolic syndrome. They are also involved in the upregulation of sterol regulatory element-binding protein-1c (SREBP-1c) and fatty acid synthase (FAS), so LXRs antagonists might have therapeutic value for hepatic steatosis \[[@B13-ijms-19-02090]\]. AR is a receptor of androgens essential for the development and maintenance of the male reproductive system and secondary male sex characteristics. AR antagonists including hydroxyflutamide (OHF) are used for treatment of androgen-dependent tumors, especially prostate tumors. GR is a receptor of cortisol, and selective antagonists of GR could be useful in treating hypercortisolemia associated with Cushing's syndrome and other conditions in which the endogenous GR is hyperactivated either through higher glucocorticoid levels or increased receptor sensitivity \[[@B14-ijms-19-02090]\]. A steroidal GR antagonist, mifepristone (RU486), shows potent activities toward other steroid receptors.

For this work, compounds **1**--**3**, **7**--**42** and **44** were prepared as described previously \[[@B9-ijms-19-02090],[@B10-ijms-19-02090],[@B15-ijms-19-02090]\]. PR-antagonistic activity was evaluated by assay of PR-regulated alkaline phosphatase activity in human breast cancer cell line T47D \[[@B10-ijms-19-02090],[@B16-ijms-19-02090]\] while RORα, RORβ and RORγ inverse agonistic activities, and LXRα, LXRβ, AR and GR antagonistic activities were evaluated by reporter gene assay in HEK293 cell line \[[@B9-ijms-19-02090],[@B10-ijms-19-02090]\]. Concentration of the agonists were set as around their EC~50~ values. Reproducibility of our assay systems is shown in [Table S1](#app1-ijms-19-02090){ref-type="app"}. First, we focused on the SAR at the 2-position of phenanthridinone. The results, including the activities of positive controls T0901317 (**6**), RU486, and OHF, are shown in [Table 1](#ijms-19-02090-t001){ref-type="table"}. We have reported that introduction of alkyl groups (**8**--**10**) or a hydroxymethyl group (**11**) at the 2-position of **7** resulted in retention or decrease of the PR-antagonistic activity \[[@B10-ijms-19-02090]\] and RORs inverse agonistic activity \[[@B9-ijms-19-02090]\]. Introduction of a hexafluoropropanol moiety somewhat increased the RORs activity and PR activity. According to the reported X-ray crystal structures of compound **6** and human LXRs LBD, the hydroxyl group of **6** forms a hydrogen bond with a histidine residue (His421 for LXRα and His435 for LXRβ) in helix 11 \[[@B17-ijms-19-02090],[@B18-ijms-19-02090]\]. The SARs for RORs and PR are broadly consistent with those of LXRs, AR, and GR. For AR and PR, introduction of a hydroxymethyl group (**11**) resulted in retention of the activity, whereas introduction of hexafluoropropanol (**12**) resulted in 6-fold and 9-fold increases of PR and AR activity, respectively. On the other hand, for LXRs and RORs, **11** showed weaker activity than **7** whereas **12** showed stronger activity than **7**, suggesting that the two trifluoromethyl groups might be associated with more potent activity and the hydroxyl group might not form a strong hydrogen bond with histidine in these receptors, in contrast to the other receptors. This idea is consistent with the reported co-crystal structure of T0901317 (**6**) complexed with RORγ \[[@B19-ijms-19-02090]\]. Overall, we found that compound **12** showed not only PR-antagonistic activity and RORs inverse agonistic activity, but also LXRα, LXRβ, AR and GR antagonistic activity ([Table 1](#ijms-19-02090-t001){ref-type="table"}). These results support our view that the phenanthridin-6(5*H*)-one scaffold acts as a steroid surrogate.

Next, SAR at the nitrogen atom is shown in [Table 2](#ijms-19-02090-t002){ref-type="table"}. Similar to the SAR for RORs, introduction of a longer-chain alkyl group on the nitrogen atom (**12** and **15**) resulted in enhancement of the GR antagonistic activity. SAR for AR was similar to that for PR, that is, hydrogen analog **12** showed potent AR antagonistic activity with an IC~50~ value of 0.10 μM, and more than 200-fold selectivity for AR over RORs and GR, and about 7.8- and 50-fold selectivity over PR and LXRs, respectively. The longest alkyl analog **17** showed decreased activity toward all NRs, suggesting that the binding pocket hosting the N-alkylated derivatives might not be able to accommodate a group larger than a hexyl group.

Next, SAR at the nitrogen atom is shown in [Table 2](#ijms-19-02090-t002){ref-type="table"}. Similar to the SAR for RORs, introduction of a longer-chain alkyl group on the nitrogen atom (**12** and **15**) resulted in enhancement of the GR antagonistic activity. SAR for AR was similar to that for PR, that is, hydrogen analog **12** showed potent AR antagonistic activity with an IC~50~ value of 0.10 μM, and more than 200-fold selectivity for AR over RORs and GR, and about 7.8- and 50-fold selectivity over PR and LXRs, respectively. The longest alkyl analog **17** showed decreased activity towards all NRs, suggesting that the binding pocket hosting the N-alkylated derivatives might not be able to accommodate a group larger than a hexyl group.

Next, the effect of introduction of a methoxy group at every position (methoxy scanning) was investigated (**18**--**24**; [Table 3](#ijms-19-02090-t003){ref-type="table"}) because many types of NR ligands possess a methoxy group(s) \[[@B20-ijms-19-02090]\]. We have reported that 3-methoxy and 4-methoxy analogs **19** and **20** showed more than 3-fold and 2-fold enhanced PR activity compared with the unsubstituted analog **12**, respectively \[[@B10-ijms-19-02090]\]. In contrast, 9-methoxy analog **23** showed 5-fold weaker PR activity than **12**. In the case of RORs, we have reported that introduction of a methoxy group at the 9-position (**23**) enhanced ROR activities \[[@B9-ijms-19-02090]\]. The activities toward LXRs, AR and GR also depended on the position of the methoxy group. 1-Methoxy analog **18** showed decreased activity for all receptors tested. Enhanced activity was observed when a methoxy group was introduced at the 4-, 9- or 10-position for LXRα, 9- or 10-position for LXRβ, 3- and 8-position for AR, and 3- or 4-position for GR. Especially, 3-methoxy analog **19** showed 5.7-fold improved GR activity compared with **12**. Overall, introduction of a methoxy group resulted in increased activity in almost all cases except RORβ, but the most suitable position depended on the NR (3-position: PR and GR, 8-position: AR, 9-position: RORα, RORγ and LXRβ, 10-position: LXRα). The introduction of a substituent at every position is useful to investigate substituent effects. In this context, it is important to note that phenanthridin-6(5*H*)-one analogs bearing substituent(s) at any position can be quite easily synthesized, and this represents a considerable advantage compared to the steroid skeleton.

The results of methoxy scanning prompted us to investigate the effect of introduction of two methoxy groups (**25**--**31** [Table 3](#ijms-19-02090-t003){ref-type="table"}). In the cases of RORα, PR, AR and GR, 3,4-dimethoxy analog **25** exhibited similar or weaker activity to the 3-methoxy and 4-methoxy analogs **19** and **20**. A possible explanation might be the direction of the two methoxy groups, that is, one or both might occupy a space not suitable for receptor interaction due to steric hindrance. This idea is supported by the fact that 3,4-dioxolane analog **26** showed stronger activity than **25** toward PR, AR and GR. Compound **26** was the most potent GR antagonist with an IC~50~ value of 0.76 μM, although this compound also showed PR and AR antagonistic activities with IC~50~ values of 0.23 and 0.54 μM, respectively. When two methoxy groups were introduced at distal positions, the activity was improved. Thus, 3,8-dimethoxy analog **27** and 4,8-dimethoxy analog **28** showed more potent PR-antagonistic activity than monomethoxy analogs **19**, **20**, and **22**, and 3,8-dimethoxy analog **27** showed more potent AR antagonistic activity than monomethoxy analogs **19** and **22**.

We next examined the SAR of fluoro derivatives **32**--**35** ([Table 4](#ijms-19-02090-t004){ref-type="table"}) to investigate the effect of this electron-withdrawing substituent. For PR, the preferences for fluorine substitution position were roughly consistent with the results of the methoxy scanning, that is, 4- and 8-substitued analogs **32** and **34** showed enhanced PR activity, whereas 9-substituted analogs **35** showed weaker PR activity \[[@B10-ijms-19-02090]\]. For AR, all fluoro analogs **32**--**35** showed enhanced activity compared with **12**, suggesting that an electron-withdrawing effect at these positions is important for AR antagonistic activity. For LXRα, 4- and 7-fluoro analogs **32** and **33** showed enhanced activity compared with **12**.

We then examined various substituents at the 9-position ([Table 5](#ijms-19-02090-t005){ref-type="table"}). We have reported that introduction of a chlorine atom at the 9-position (**2**) enhanced inverse agonistic activity toward RORγ \[[@B9-ijms-19-02090]\]. The SARs of RORγ were roughly consistent with the results for LXRβ, and **2** also exhibited potent LXRβ antagonistic activity with the IC~50~ value of 0.88 μM. Replacement of fluorine at the 9-position (**35**) with chlorine (**2**) caused enhanced activity toward RORs and LXRβ, but decreased activity toward PR, AR, and GR, suggesting that molecular modification at the 9-position would be important to improve selectivity for metabolic NRs over steroid receptors.

Next, we focused on the 4-position ([Table 6](#ijms-19-02090-t006){ref-type="table"}), because 4-methoxy analog **20** showed enhanced RORα, LXRα and PR activity, and 4-fluoro analog **32** showed enhanced LXRα, PR and AR activity. Compounds **39**--**44** and **2** showed weak activity toward RORs and GR, indicating that the alkyl group on the nitrogen atom is important for activity toward these receptors. We have reported that 4-alkyl analogs **40**--**42** showed greater PR activity than the unsubstituted analog **1**, and 4-methyl analog **40** had an IC~50~ value of 0.15 µM \[[@B10-ijms-19-02090]\]. As for LXRs and AR, 4-alkyl analogs **40**--**42** showed decreased activity compared with the unsubstituted analog **1**, whereas 4-fluoro analog **32** showed greater activity than **1**. Based on the reported SARs of non-steroidal AR antagonists, an electron-withdrawing substituent neighboring the amide bond is expected to be important for potent AR antagonism \[[@B21-ijms-19-02090]\]. Therefore, 4-chloro analog **43** was designed and synthesized as shown in [Scheme 1](#ijms-19-02090-sch001){ref-type="scheme"}. Interestingly, **43** showed greater AR activity and weaker RORs, LXRs, PR and GR activity than 4-fluoro analog **32**. Compound **43** showed the IC~50~ value of 0.059 μM, being 2.9-fold more potent than clinically used OHF under our assay conditions. Compound **43** showed more than 340-fold selectivity over RORs and LXRβ, and 90-fold and 6-fold selectivity over LXRα and PR, respectively. This result indicates that molecular modification at the 4-position can increase selectivity for AR over the other NRs.

Chronic administration of AR antagonists often leads to the development of resistance. Mutations in the LBD of AR, such as T877A, have been identified in patients treated with flutamide ([Figure 2](#ijms-19-02090-f002){ref-type="fig"}), and the activated metabolite, hydroxyflutamide, is an agonist of AR bearing T877A \[[@B22-ijms-19-02090]\]. In contrast, another AR antagonist, enzalutamide, was reported to antagonize AR mutant T877A \[[@B23-ijms-19-02090]\]. Thus, development of a novel chemical class of AR antagonists, different from flutamide analogs seems an attractive approach for the treatment of AR antagonist-resistant cancer, providing further motivation to evaluate steroid surrogates. Therefore, we investigated the antiandrogenic activity of several potent AR antagonists by means of PSA (prostate-specific antigen, an AR-regulated gene) ELISA (enzyme-linked immunosorbent assay) in human prostate cancer cell line LNCaP, which has T877A mutation in the AR LBD. Potent AR antagonist **43** did not show antiandrogenic activity in LNCaP, whereas several other AR antagonists including **33** decreased the PSA level with an IC~50~ of 190 nM ([Table 7](#ijms-19-02090-t007){ref-type="table"}). This result suggests that the new non-flutamide type AR antagonist **33** is a promising candidate for antiandrogen therapy of prostate cancer.

3. Materials and Methods {#sec3-ijms-19-02090}
========================

3.1. Chemistry {#sec3dot1-ijms-19-02090}
--------------

### 3.1.1. General {#sec3dot1dot1-ijms-19-02090}

^1^H NMR spectra were recorded on a JNM-ECA500 (500 MHz) spectrometer (JEOL Ltd., Tokyo, Japan). Chemical shifts (δ) are reported in parts per million. Flash column chromatography was performed on silica gel 60N (40--50 mm) (Kanto Chemical Co., Inc., Tokyo, Japan). HPLC analyses to check purity were performed on an analytical column (GL Science Inc., Tokyo, Japan) Inertsil ODS-4 reversed-phase column, 5 μm, 4.6 mm × 150 mm) eluted with a mobile phase consisting of CH~3~CN/water at a flow rate of 1.0 mL/min, with UV (ultraviolet) monitoring at 254 nm, at 37 °C.

### 3.1.2. 2-(4-Amino-3-chlorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (**46**) {#sec3dot1dot2-ijms-19-02090}

To a solution of 2-chloroaniline (**45**) (1.58 mL, 15.0 mmol) in toluene (11 mL) were added hexafluoroacetone trihydrate (2.06 mL, 18.0 mmol) and *p*-TsOH (258 mg, 1.50 mmol). The mixture was stirred for 8.5 h at 110 °C, and then cooled to room temperature. Water was added, and the resulting mixture was extracted with AcOEt. The combined organic layer was washed with brine, dried over Na~2~SO~4~, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (*n*-hexane/AcOEt = 10:1-3:1) to give **46** as a pink solid (9%). ^1^H NMR (500 MHz, CDCl~3~) δ: 7.58 (s, 1H), 7.35 (d, *J* = 8.6 Hz, 1H), (d, *J* = 9.2 Hz, 1H).

### 3.1.3. *N*-(2-Chloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-iodobenzamide (**47**) {#sec3dot1dot3-ijms-19-02090}

To a solution of EDC (742 mg, 3.87 mmol) and DMAP (473 mg, 3.87 mmol) in DMF (4.0 mL) was added 2-iodobenzoic acid (640 mg, 2.58 mmol) under an Ar atmosphere. The mixture was stirred for 30 min at room temperature, then **46** (379 mg, 1.29 mmol) was added to it, and stirring was continued at 100 °C for 4 h. The resulting mixture was cooled, diluted with water, and extracted with AcOEt. The combined organic layer was washed with brine, dried over Na~2~SO~4~, and concentrated under reduced pressure. The residue was purified by column chromatography (*n*-hexane/AcOEt = 4:1) to give **47** (181 mg, 0.346 mmol, 27%) as a brown solid. ^1^H NMR (500 MHz, DMSO-*d~6~*) δ: 7.94 (d, *J* = 8.0 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 1H), 7.76 (d, *J* = 1.7 Hz, 1H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 4.6 Hz, 2H), 7.24 (td, *J* = 3.9, 1.3 Hz, 1H).

### 3.1.4. *N*-(2-Chloro-4-(1,1,1,3,3,3-hexafluoro-2-((2-(trimethylsilyl)ethoxy)methoxy)propan-2-yl)phenyl)-2-iodo-*N*-((2-(trimethylsilyl)ethoxy)methyl)benzamide (**48**) {#sec3dot1dot4-ijms-19-02090}

Sodium hydride (41.6 mg, 1.04 mmol) was added to a solution of **47** (181 mg, 0.346 mmol) in DMF (1.5 mL) at 0 °C. The mixture was stirred for 1 h at 0 °C, then SEMCl (184 μL, 1.04 mmol) was added at 0 °C, and stirring was continued for 6 h at room temperature. The resulting mixture was diluted with AcOEt, quenched with water, and extracted with AcOEt. The combined organic layer was washed with water, dried over Na~2~SO~4~, and concentrated. The residue was purified by column chromatography (*n*-hexane/AcOEt = 20:1 to 10:1) to give **48** (219 mg, 0.279 mmol) as a colorless oil. The compound was used for the next reaction without further purification.

### 3.1.5. 4-Chloro-2-(1,1,1,3,3,3-hexafluoro-2-((2-(trimethylsilyl)ethoxy)methoxy)propan-2-yl)-5-((2-trimethylsilyl ethoxy)methyl)phenanthridin-6(5*H*)-one (49) {#sec3dot1dot5-ijms-19-02090}

To a solution of **48** (219 mg, 0.279 mmol) in DMA (1.0 mL) were added PCy~3~·HBF~4~ (63.7 mg, 0.173 mmol), Cs~2~CO~3~ (620 mg, 1.90 mmol) and Pd(OAc)~2~ (12.0 mg, 0.0532 mmol) under an Ar atmosphere. The mixture was stirred for 3 h at 130 °C, then cooled to room temperature, and water was added. The resulting mixture was extracted with AcOEt. The combined organic layer was washed with brine, dried over Na~2~SO~4~, and concentrated under reduced pressure. The residue was purified by column chromatography (*n*-hexane/AcOEt = 20:1) to give **49** as a brown oil (45.2 mg, 0.0824 mmol, 24% in 2 steps). ^1^H NMR (500 MHz, CDCl~3~) δ: 8.56 (s, 1H), 8.53 (dd, *J* = 8.0, 1.1 Hz, 1H), 8.26 (d, *J* = 7.7, 1.5 Hz, 1H), 7.62 (t, *J* = 8.0 Hz, 1H), 7.47 (s, 1H), 5.85 (s, 2H), 4.95 (s, 2H), 3.88 (t, *J* = 8.6 Hz, 2H), 3.74 (t, *J* = 8.3 Hz, 2H), 1.02 (t, *J* = 8.3 Hz, 2H), 0.98 (m, 2H), 0.02 (s, 9H), −0.05 (s, 9H).

### 3.1.6. 4-Chloro-2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenanthridin-6(5*H*)-one (**43**) {#sec3dot1dot6-ijms-19-02090}

TBAF (1 M in THF, 0.779 mL, 0.779 mmol) was added to a solution of **49** (42.7 mg, 0.0779 mmol) in THF (0.8 mL) at room temperature. The reaction mixture was stirred under reflux for 9 h, then diluted with water, and extracted with AcOEt. The combined organic layer was washed with brine, dried over Na~2~SO~4~, and concentrated under reduced pressure. The residue was purified by column chromatography (CHCl~3~/MeOH = 40:1) to give **43** as a pale yellow solid (18%).

^1^H NMR (500 MHz, DMSO-*d~6~*) δ: 8.35 (d, *J* = 8.6 Hz, 1H), 8.27 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.86--7.83 (m, 1H), 7.68 (d, *J* = 8.6 Hz, 1H), 7.63 (t, *J* = 7.4 Hz, 1H), 7.41 (d, *J* = 8.6 Hz, 1H). HLPC purity 97.0% (area %).

3.2. Biology {#sec3dot2-ijms-19-02090}
------------

### 3.2.1. T-47D Alkaline Phosphatase Assay {#sec3dot2dot1-ijms-19-02090}

T-47D alkaline phosphatase assays were performed as described in the literature \[[@B10-ijms-19-02090]\]. Briefly, human ductal breast epithelial tumor (T-47D) cells were treated with fresh medium containing test compound plus progesterone (final concentration 1 nM), and incubated for 24 h. The fixed cells were washed with PBS and assay buffer was added. After the reaction was terminated, the absorbance at 405 nm was measured. All data points were measured in triplicate.

### 3.2.2. Reporter Gene Assay {#sec3dot2dot2-ijms-19-02090}

Human embryonic kidney (HEK) 293 cells (RIKEN BRC, Ibaraki, Japan) were maintained in DMEM (Dulbecco's Modified Eagle's medium) containing 5% (*v*/*v*) fetal bovine serum, and penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO~2~ in air. Cells were seeded in clear-bottomed white 96-well plates at a density of 1 × 10^4^ cells/well and incubated for 6 h prior to transfection. Cells were co-transfected with 30 ng of a NR expression plasmid, 50 ng of a luciferase reporter and 10 ng of CMX-β-galactosidase expression vector per well, using the calcium phosphate co-precipitation method. After 24 h, transfected cells were treated with dimethyl sulfoxide (DMSO) or DMSO solution of test compounds for 24 h. T0901317 (0.3 μM), T0901317 (0.1 μM), dihydrotestosterone (0.3 nM), and dexamethasone (1 nM) were used as agonists for LXRα, LXRβ, AR and GR, respectively. After addition of a luciferase substrate, luminescence was detected with a luminometer. The luciferase activity of each sample was normalized by β-galactosidase activity: 2-nitrophenyl-β-[d]{.smallcaps}-galactopyranoside was added, and the absorbance was measured at 405 nm. Each sample was carried out in triplicate. A six-point sigmoidal dose-response curve was generated for each compound. The IC~50~ value for each compound was calculated by linear approximation of two points adjacent to 50% inhibition with logarithmic scale. In [Table S1](#app1-ijms-19-02090){ref-type="app"}, biological reproducibility are reported as the mean IC~50~ ± SEM.

Nuclear receptor plasmids: GR (CMX-hGR), AR (CMX-hAR), ROR (pcDNA3.1(-)-hRORα1, pcDNA3.1(-)-hRORβ1, pcDNA3.1(-)-hRORγ1), LXR (CMX-GAL4N-hLXRα-LBD, CMX-GAL4N-hLXRβ-LBD).

Luciferase reporter plasmids: GR (MTV-Luc), AR (ARE-Luc), ROR (RORE-TK-Luc), LXR (TK-MH100x4-Luc).

Plasmids for AR, GR and LXRs were provided by Prof. Dr. Makishima, and plasmids for RORs were provided by Itsuu Institute (Kanagawa, Japan).

### 3.2.3. PSA Level in LNCaP Cell Line {#sec3dot2dot3-ijms-19-02090}

The human prostate cancer cell line LNCaP (ECACC, London, UK) was routinely maintained in RPMI1640 containing 10% (*v*/*v*) fetal bovine serum, and penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO~2~ in air. Cells were cultured in RPMI1640 without phenol red containing 10% (*v*/*v*) charcoal-stripped fetal bovine serum, and penicillin/streptomycin at 37 °C in a humidified atmosphere of 5% CO~2~ in air for 3 days. Then cells were plated in 96-well plates at 1 × 10^4^ cells/well and incubated overnight. On the next day, cells were treated with fresh media containing test compound plus dihydrotestosterone (final concentration 10 nM), and incubated for 48 h. Then, PSA levels were measured in the culture supernatants, after 100-fold dilution with the medium, using ELISA (Immunospec Corp., CA, USA Free prostate-specific antigen cat. \#E29-212) according to the manufacturer's instructions. All data points were carried out twice in triplicate.

4. Conclusions {#sec4-ijms-19-02090}
==============

Development of non-steroidal NR ligands is desirable to obtain safer, more selective agents for clinical use. Here, non-steroidal antagonists for multiple target proteins including LXRβ (IC~50~: 0.88 μM), AR (IC~50~: 0.10 μM), GR (IC~50~: 0.76 μM) were efficiently identified by exhaustive evaluation of a small steroid surrogate library. In addition, a potent AR antagonist **43** (IC~50~: 0.059 μM) belonging to a new chemical class was developed. Further, AR antagonist **33** showed antiandrogenic activity toward AR antagonist-resistant cell line LNCaP with the IC~50~ value of 190 nM. Structure-activity relationship studies of phenanthridinone analogs revealed that (1) hydrogen at the nitrogen is important for AR and PR activity, and a longer alkyl group is favorable for RORs and GR activity, (2) molecular modification at the 9-position can increase selectivity for metabolic NRs over steroid receptors, and (3) an electron-withdrawing substituent on the phenyl group is important for AR antagonistic activity, while modification at the 4-position can increase selectivity for AR over other NRs. The phenanthridinone skeleton is more readily modifiable than the steroid skeleton. Thus, our strategy of efficient lead finding, activity enhancement and preliminary control of selectivity over other receptors should expand the utility of the multi-template approach, even though the compounds obtained here still require further optimization.

Supplementary materials can be found at <http://www.mdpi.com/1422-0067/19/7/2090/s1>.
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![Chemical structures of endogenous steroidal ligands for NRs and phenanthridinone ligands for target proteins that recognize endogenous steroidal ligands.](ijms-19-02090-g001){#ijms-19-02090-f001}

![Reagents and conditions: (a) CF~3~COCF~3~·1.5H~2~O, *p*-TsOH·H~2~O, toluene, reflux, 27%; (b) 2-iodobenzoic acid, EDC, DMAP, DMF, 100 °C; (c) SEMCl, NaH, DMF, 0 °C to RT; (d) Pd(OAc)~2~, PCy~3~·HBF~4~, Cs~2~CO~3~, DMA, 130 °C, 24% in 2 steps; (e) TBAF, THF, reflux, 18%.](ijms-19-02090-sch001){#ijms-19-02090-sch001}

![Chemical structures of AR antagonists.](ijms-19-02090-g002){#ijms-19-02090-f002}

ijms-19-02090-t001_Table 1

###### 

SAR at 2-position.

![](ijms-19-02090-i001)

  Compound   R               RORα ^1^   RORβ ^1^   RORγ ^1^   LXRα ^2^   LXRβ ^2^   PR ^2,3^   AR ^2^   GR ^2^
  ---------- --------------- ---------- ---------- ---------- ---------- ---------- ---------- -------- ----------
  **6**      \-              \>20,000   \>20,000   6500       290 ^4^    130 ^4^                        
  RU486      \-                                                                     0.073               2.0
  OH-Flu     \-                                                                                170      
  **7**      H               10,000     13,000     15,000     19,000     15,000     7100       17,000   \>20,000
  **8**      Me              18,000     17,000     17,000     17,000     16,000     7900       11,000   \>20,000
  **9**      Et              9000       7900       9200       17,000     16,000     7800       19,000   19,000
  **10**     *t*-Bu          12,000     13,000     10,000     \>20,000   \>20,000   8300       17,000   \>20,000
  **11**     CH~2~OH         \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   8600       9600     \>20,000
  **12**     (CF~3~)~2~COH   9800       6500       3900       8400       3700       1200       1800     7400

^1^ Inverse agonistic activity (IC~50~: nM) \[[@B9-ijms-19-02090]\]. ^2^ Antagonistic activity (IC~50~: nM). ^3^ \[[@B10-ijms-19-02090]\]. ^4^ Agonistic activity (IC~50~: nM).

ijms-19-02090-t002_Table 2

###### 

SAR at nitrogen atom.

![](ijms-19-02090-i002)

  Compound   R               RORα ^1^   RORβ ^1^   RORγ ^1^   LXRα ^2^   LXRβ ^2^       PR ^2,3^   AR ^2^   GR ^2^
  ---------- --------------- ---------- ---------- ---------- ---------- -------------- ---------- -------- ----------
  **1**      H               \>20,000   \>20,000   \>20,000   5000 ^4^   5100 ^4^       780        100      \>20,000
  **13**     Me              \>20,000   \>20,000   \>20,000   4100 ^4^   \>20,000 ^4^   340        500      \>20,000
  **14**     Et              \>20,000   \>20,000   \>20,000   14,000     6600           1400       1700     \>20,000
  **15**     *n*-Pr          11,000     8200       4200       12,000     6900           3800       5600     17,000
  **16**     *n*-Hex         7600       5400       4700       16,000     10,000         2500       4000     \>20,000
  **17**     *n*-C~9~H~19~   \>20,000   \>20,000   \>20,000   \>20,000   \>20,000       10,000     15,000   \>20,000

^1^ Inverse agonistic activity (IC~50~: nM) \[[@B9-ijms-19-02090]\]. ^2^ Antagonistic activity (IC~50~: nM). ^3^ \[[@B10-ijms-19-02090]\]. ^4^ \[[@B8-ijms-19-02090]\].

ijms-19-02090-t003_Table 3

###### 

SAR of substitution effect of alkoxy groups.

![](ijms-19-02090-i003)

  Compound   R               RORα ^1^   RORβ ^1^   RORγ ^1^   LXRα ^2^   LXRβ ^2^   PR ^2,3^   AR ^2^     GR ^2^
  ---------- --------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  **18**     1-OMe           \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   4000       \>20,000   \>20,000
  **19**     3-OMe           8200       8200       7500       8400       9200       410        1100       1300
  **20**     4-OMe           7500       6900       5400       6900       5500       560        2400       3900
  **21**     7-OMe           12,000     15,000     13,000     11,000     12,000     12,000     9400       14,000
  **22**     8-OMe           12,000     15,000     13,000     12,000     11,000     1100       1000       8200
  **23**     9-OMe           6600       7200       2700       7000       2400       5800       \>20,000   10,000
  **24**     10-OMe          7700       \>20,000   8500       4600       4300       2700       \>20,000   \>20,000
  **25**     3,4-diOMe       \>10,000   \>10,000   8500       8500       9600       510        6100       \>20,000
  **26**     3,4-(OCH~2~O)   \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   230        540        760
  **27**     3,8-diOMe       9500       13,000     12,000     17,000     18,000     300        580        1700
  **28**     4,8-diOMe       11,000     11,000     9700       \>10,000   \>10,000   340        1700       5200
  **29**     7,8-diOMe       7300       7700       8000       3200       3200       4200       4600       7900
  **30**     7,9-diOMe       \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   \>20,000
  **31**     8,9-diOMe       18,000     16,000     19,000     8800       8900       9600       1600       17,000

^1^ Inverse agonistic activity (IC~50~: nM) \[[@B9-ijms-19-02090]\]. ^2^ Antagonistic activity (IC~50~: nM). ^3^ \[[@B10-ijms-19-02090]\].

ijms-19-02090-t004_Table 4

###### 

SAR of substitution effect of fluorine atom.

![](ijms-19-02090-i004)

  Compound   Position   RORα ^1^   RORβ ^1^   RORγ ^1^   LXRα ^2^   LXRβ ^2^   PR ^2,3^   AR ^2^   GR ^2^
  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- -------- ----------
  **32**     4          15,000     14,000     18,000     3100       4600       130        390      6900
  **33**     7          7900       9800       13,000     3100       3100       730        460      9800
  **34**     8          17,000     11,000     \>20,000   7900       6000       310        680      \>20,000
  **35**     9          9800       8300       5000       6400       5400       1000       920      7000

^1^ Inverse agonistic activity (IC~50~: nM) \[[@B9-ijms-19-02090]\]. ^2^ Antagonistic activity (IC~50~: nM). ^3^ \[[@B10-ijms-19-02090]\].

ijms-19-02090-t005_Table 5

###### 

SAR of substitution effect at 9-posiiton.

![](ijms-19-02090-i005)

  Compound   R       RORα ^1^   RORβ ^1^   RORγ ^1^   LXRα ^2^   LXRβ ^2^   PR ^2,3^   AR ^2^     GR ^2^
  ---------- ------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  **36**     Me      7600       7100       1000       12,000     3000       3700       6400       16,000
  **2**      Cl      5600       4900       690        9200       880        4300       5200       10,000
  **37**     CF~3~   5500       5600       2600       7100       4500       4200       \>20,000   \>20,000
  **38**     OH      6400       5500       4100       7000       5500       5100       \>3000     \>20,000

^1^ Inverse agonistic activity (IC~50~: nM) \[[@B9-ijms-19-02090]\]. ^2^ Antagonistic activity (IC~50~: nM). ^3^ \[[@B10-ijms-19-02090]\].

ijms-19-02090-t006_Table 6

###### 

SAR at 4-posiiton and other substitution effects.

![](ijms-19-02090-i006)

  Compound     R           RORα ^1^   RORβ ^1^   RORγ ^1^   LXRα ^2^   LXRβ ^2^   PR ^2,3^   AR ^2^     GR ^2^
  ------------ ----------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  **39**       4-OMe       \>20,000   \>20,000   9600       \>20,000   \>20,000   270        \>20,000   \>20,000
  **40**       4-Me        \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   150        \>20,000   \>20,000
  **41**       4-Et        \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   210        14,000     \>20,000
  **42**       4-*n*-Pr    \>20,000   11,000     9900       \>20,000   20,000     360        5400       16,000
  **43**       4-Cl        \>20,000   \>20,000   \>20,000   5300       \>20,000   350        59         \>20,000
  **44** ^3^   4-Me, 8-F   \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   46         1700       \>20,000
  **3** ^3^    \-          \>20,000   \>20,000   \>20,000   \>20,000   \>20,000   27         300        \>20,000

^1^ Inverse agonistic activity (IC~50~: nM) \[[@B9-ijms-19-02090]\] ^2^ Antagonistic activity (IC~50~: nM). ^3^ \[[@B10-ijms-19-02090]\].

ijms-19-02090-t007_Table 7

###### 

Antiandrogenic activity toward AR antagonist-resistant cell line LNCaP.

  Compound   AR Reporter Gene IC~50~ (nM)   LNCaP IC~50~ (nM) ± SEM
  ---------- ------------------------------ -------------------------
  **1**      100                            \>10,000
  **13**     500                            \>10,000
  **26**     540                            560 ± 260 (*N* = 2)
  **32**     390 ± 30 (*N* = 2)             490 ± 260 (*N* = 2)
  **33**     460                            190 ± 95 (*N* = 2)
  **34**     680                            \>10,000
  **35**     920                            550 ± 110 (*N* = 2)
  **43**     59 ± 9.5 (*N* = 2)             \>10,000

Mean IC~50~ values with standard error of mean (SEM) from 1 or N times independent experiments.
